Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL

Next Previous
Trial Profile

A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Obinutuzumab; Rituximab; Venetoclax
  • Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acerta Pharma

Most Recent Events

  • 12 Dec 2023 Results of pooled analysis from CL001 , CL003 , CL006, CL007 and CL309 , presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 29 Nov 2023 According to an AstraZeneca media release, analysis of 5 studies (CL-001, CL-003, CL-006, CL-007 & CL-309) showing acceptable safety outcomes based on rates of nonfatal and fatal ventricular arrhythmias and sudden death in patients with CLL will be presented at 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023.
  • 16 Oct 2023 Planned End Date changed from 25 Aug 2026 to 6 Sep 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top